In October 2025, Dr. Shah delivered an insightful presentation on novel treatment options for Hodgkin Lymphoma (HL). During his talk, he reviewed the primary therapies historically used to treat HL and shared updates on the evolving standard of care.

Dr. Shah emphasized that the current frontline treatment for HL is now Niv-AVD combined with XRT, replacing the long-standing ABVD regimen. This updated approach has demonstrated improved patient outcomes compared to older treatment protocols.

His presentation also highlighted the critical role of nurses in patient care—particularly in monitoring treatment responses, managing side effects, and providing essential support throughout the therapy process.